TABLE 1.

Summary of the ability of various anti-HIV-1 antibodies to inhibit the binding of 4KG5 scFv to gp120JR-FL

Antibody identificationAntibody specificityEffect of antibody (30 μg/ml) on 4KG5 binding to gp120JR-FLb
p35C1 (d)a0
522-149C1 (d)0
G3-4V2 (d)I ↓
G3-136V2 (d)I ↓
19bV3 loopI ↓↓↓
447-52DV3 loopI ↓↓↓
hNM01V3 loopI ↓↓
AH48cV3 loopI ↓↓↓
loop2V3 loopI ↓↓↓
F425 B4e8V3 loopI ↓↓↓
694-88DV3 loopI ↓↓↓
G3-299C4-V3 (d)I ↓
G3-42C4-V3 (d)I ↓
G3-519C4I ↓
G3-537C4I ↓
b12CD4bsE ↑
b6CD4bsI ↓↓↓
b3CD4bsI ↓↓
F91CD4bsI ↓↓
F105CD4bsI ↓↓
15eCD4bsI ↓↓↓
L33CD4bsI ↓↓
1008-DCD4bsI ↓↓
654-30DCD4bsI ↓↓
559-64DCD4bsI ↓↓
1027-30DCD4bsI ↓↓
Ia3cCD4bsI ↓↓
Ia7cCD4bsI ↓↓
FG39cCD4bsI ↓
Fbb14cCD4bs0
sCD4true CD4bsI ↓
A32C1-C4 (CD4i)0
17bCD4i0
X5CD4i0
48dCD4i0
Fbb21cCD4i0
2G12Carbohydrate (outer face)0
1C1C50
M91C50
670-DC50
1331AC50
D7324C5 (polyclonal)0
KZ52Ebola group0
FDA2Patient serum (polyclonal)I ↓↓
HIVIGPooled HIV-1+ human IgG (polyclonal)I ↓↓
  • a d, discontinuous (epitope).

  • b 4KG5 was used at a concentration previously determined to result in ∼75% maximal binding (∼0.3 μg/ml), and was detected via the hexahistidine tag by using the India-HIS probe reagent (Pierce). 0, 75 to 110% maximal binding (i.e., no effect); I, inhibition; ↓ 50 to 74% maximal binding; ↓↓, 25 to 49% maximal binding; ↓↓↓, <25% maximal binding; E, enhancement (emphasized with bold type); ↑, >130% maximal binding.

  • c Novel human antibody identified in this study.